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THE ROLE OF PRIMARY CILIA IN CARTILAGE HEALTH AND DISEASE
M.M. Knight. Inst. of Bioengineering, Queen Mary Univ. of London,
London, United Kingdom
Primary cilia are microtubule-based organelles consisting of a single
membrane bound axoneme that projects into the extracellular micro-
environment, functioning as a centre for various signalling pathways
including hedgehog (Hh) andWnt signalling andmechanotransduction.
The length of cilia is proposed to modulate their function, and is gov-
erned, in part, by intraﬂagellar transport (IFT), the process used to trafﬁc
ciliary components along the axoneme. In chondrocytes the primary
cilium is 1–3 mm in length and expressed in approximately 40–80% of
cells (Fig. 1). Mutation of IFT proteins, which control ciliogenesis, results
in skeletal patterning abnormalities including defects in growth plate
and developing cartilage. Cartilage speciﬁc loss of IFT88 results in
chondrocytes with stunted or no cilia and OA-like degeneration of
articular cartilage. Other studies demonstrate that primary cilia are
required for chondrocyte mechanotransduction and associated extra-
cellular matrix synthesis. Thus primary cilia are important for both
development and maintenance of healthy cartilage. Primary cilia are
also involved in osteoarthritis (OA) with studies showing that cilia-
mediated Hh signalling is aberrantly up-regulated in OA leading to
accelerated degradation of the cartilage extracellular matrix. These
studies demonstrated that pharmaceutical or genetic inhibition of Hh
signalling dramatically reduces the severity of cartilage degradation by
reducing expression of the matrix metalloproteinase, ADAMTS5. Simi-
larly, Wnt signalling has also been shown to be involved in OA and, like
Hh signalling involves the primary cilium. However the mechanisms
through which OA triggers alterations in cilia-mediated Hh and Wnt
signalling are as yet, unknown. Previous studies indicate that primary
cilia expression is greater in OA tissue. Furthermore studies from our
group reveal that primary cilia length is inﬂuenced by environmental or
pathological stimuli including inﬂammatory cytokines, HIFs, mechan-
ical loading, substrate stiffness and topography and heat shock. These
changes in cilia length are associated with modulation of Wnt and Hh
signalling. We therefore hypothesise that primary cilia are not only
essential for cartilage health, but that pathological changes in the
chondrocyte microenvironment lead to alterations in cilia structure and
associated function, thereby regulating cartilage pathogenesis. Thus we
suggest that OA may be treated as an ‘environmental’ ciliopathy.
To summarise, it is increasingly clear that chondrocyte primary cilia are
important in cartilage development, health and disease and that
changes in cilia structure are linked to alterations in key signalling
pathways. By understanding the mechanism which result in aberrant
alteration in cilia structure and function we hope to open the door to
new therapeutic approaches for controlling OA and associated cartilage
degradation.Fig. 1. Confocal immunoﬂuorescence image of articular chondrocytes cultured in
monolayer with primary cilia labelled with anti-acetylated alpha tubulin (green).
Nuclei labelled with Dapi (Blue). Scale bar indicates 5 microns.I-5
ROLE OF TAI CHI IN OSTEOARTHRITIS
C. Wang. Tufts Med. Ctr., Boston, MA, USA
Symptomatic osteoarthritis, the most frequent cause of dependency in
lower limb tasks, is associated with chronic pain, physical and
psychosocial disability, reduced quality of life, and substantial health-
care costs worldwide. Currently, no effective disease-modifying reme-
dies are available for OA. However, Tai Chi, an ancient Chinese exercise
discipline, that uses an integrated mind-body approach may offer
potential therapeutic beneﬁts to patients suffering from OA.
Clinical trials and observational studies provide encouraging evidence
suggesting that the physical components of Tai Chi may enhance
cardiovascular function, muscular strength, proprioceptive acuity,
neuromuscular activity, balance, and joint stability. In addition, the
mental components of Tai Chi uniquely promote integration of mind
and body to reduce pain, and may also improve self-efﬁcacy, psycho-
logical well-being, and life satisfaction. Combined, the component
effects may reduce pain, improve function, and slow the disease
progression and disability associated with OA.
As the demand and evidence for complementary and alternative ther-
apies grows, educating healthcare providers and patients about the
evidence and clinical implications for these remedies is vital. Healthcare
providers should be able to discuss the evidence behind these treat-
ments with patients to enable them to make informed decisions.
Furthermore, by providing practical information about methods, costs,
and experience, healthcare providers can effectively encourage their
patients to explore the options for integrating western and eastern
medicines.
This workshop will 1) offer a brief history and conceptual overview of
Tai Chi, 2) elucidate the multidimensional theoretical model of Tai Chi
as a treatment for OA, 3) review the current body of knowledge on the
therapeutic beneﬁts of Tai Chi for pain and symptom relief in patients
with OA, 4) offer strategies for implementing complementary and
integrative approaches into clinical practice.
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DEVELOPMENT OF ARTICULAR CARTILAGE
M. Paciﬁci. Children's Hosp. of Philadelphia, Philadelphia, PA, USA
Limb synovial joints are structurally and biomechanically complex and
critically important structures. They are composed of articular cartilage
that covers each end of the opposing skeletal elements, synovial ﬂuid
that provides lubrication and nourishment to the tissues, ligaments that
hold the skeletal elements in register, and a ﬁbrous capsule that
delimits and deﬁnes the joints from the surrounding tissues and envi-
ronment. In addition, the joints exhibit functionally diverse shapes and
organizations as exempliﬁed by the nearly spherical convex femoral
head articulating into a nearly spherical concave hip acetabulum or the
femoral condyles articulating in complementarily-shaped tibial
plateaus. Though few in number, the joint tissues are highly specialized
in structure and function as well. Articular cartilage is characterized by
a unique and abundant extracellular matrix endowed with critical
biomechanical resilience, is largely avascular, and is able to persist
through life with relatively minor turnover of its cells and components.
Interest in synovial joints has remained unabated for decades, a reﬂec-
tion of their fundamental importance for organism function and quality
of life and for their susceptibility to a variety of acquired and congenital
conditions, most commonly osteoarthritis (OA). This has led to
continuous research efforts in this ﬁeld that have focused on joints’
structural components, biomechanics, molecular genetics and acquired
and congenital conditions. However, what remains poorly understood
at the moment are the developmental mechanisms by which synovial
joints form during embryogenesis and acquire their functional charac-
teristics and organization. This type of information – if available – could
have signiﬁcant translational medicine ramiﬁcations, particularly in
terms of designing novel tissue regeneration or reconstruction thera-
pies that could mimic and recapitulate the developmental processes. In
this talk, I will provide a comprehensive review of advances in this ﬁeld
that have been made in recent years by several research groups
including ours, with special attention to articular cartilage. For instance,
it has become clear that limb joints largely derive from a specialized
subset of progenitor cells called the mesenchymal interzone. It is also
evident that a number of signaling pathways converge in the delinea-
tion and progression of joint formation and maintenance of aricular
Abstracts / Osteoarthritis and Cartilage 21 (2013) S1–S8 S3cartilage, including the hedgehog, Wnt and TGFb pathways. Very recent
evidence indicates that the chemokine MCP-5 (monocyte-chemo-
attractant protein-5) has an important role in joint formation as well.
Intriguingly, some of these pathways and factors appear to exert also
pathogenic roles in OA later in life, reiterating the concept that research
advances on the developmental biology of joints have and will have
broad biomedical relevance and signiﬁcant therapeutic implications.
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CLINICAL PROTEOMICS
P. Fernandez-Puente. Rheumatology Div., Proteomics Group-ProteoRed/
ISCIII, INIBIC-CHUAC, A Coruña, Spain
Purpose: The diagnosis methods currently available for Osteoarthritis
(OA) are limited and lack sensitivity. Therefore, there is a considerable
interest pointed in identifying new speciﬁc biological markers for
cartilage degradation, both to facilitate early diagnosis of joint
destruction and to improve the prognosis and evaluation of disease
progression. In the recent years, shotgun proteomics strategies have
demonstrated an impressive capacity for the discovery and validation of
OA biomarkers, allowing the identiﬁcation of proteins with putative
usefulness for the early diagnosis of the disease, prognosis studies and
monitorization of alternative therapies.
Methods: We have employed proteomic tools for OA research, that
enable the large-scale relative quantiﬁcation of hundreds of proteins
between samples obtained from different conditions. The approaches
that have been followed are essentially based in the differential labeling
of peptides with isobaric tags (iTRAQ) and the subsequent multidi-
mensional liquid-chromatography separation of the mixture coupled to
tandem mass spectrometry (LC-MS/MS) analysis. By these means, both
tissue samples (articular cartilage) and bioﬂuids (serum) from OA
patients and healthy donors have been analyzed.
Results: The proteomic analysis of the serum samples led to the iden-
tiﬁcation of around 345 different proteins. A relative quantiﬁcation of
these proteins was obtained between OA patients at different stages of
the disease (K/L grade II or grade IV) and controls. This study led to the
identiﬁcation of 29 proteins that whose abundance was different in the
serum of OA patients (17 increased and 12 decreased) when compared
to healthy donors (p< 0.05). From these, 12 were altered independently
of the degree of the disease, 6 were modiﬁed only in early stages (grade
II), and 11 exclusively in advanced OA (grade IV). The reported altered
proteins, which are novel putative OA biomarker candidates, are
involved in a wide range of biological functions, such as immune
response, inﬂammation processes, lipid metabolism, oxidative stress
defence, transport or cell adhesion. In full thickness cartilage, the pro-
teomic study allowed the identiﬁcation of 339 distinct proteins. As
expected, those proteins identiﬁed with a higher number of peptides
are cartilage extracellular matrix molecules, such as type II collagen,
prolargin, aggrecan, biglycan or COMP. A quantitative comparison was
carried out to identify those proteins with a differential localization
according to the tissue layers in healthy cartilage (superﬁcial, inter-
mediate or deep). An increased abundance of type VI collagen, small
proteoglycans (mimecan, lumican or PRG4) and proteins involved in cell
adhesion processes (gelsolin, vitronectin, tenascins) was detected in the
superﬁcial layer. On the other hand, the intermediate layer was char-
acterized by a high presence of type II, V, IX and XXVIII collagens,
cartilage intermediate layer proteins (CILPs), COMP, vitrin and decorin.
Finally, the deep layer exhibited an increased abundance of type I and XI
collagens, aggrecan and bone-related proteins (bone sialoprotein 2,
osteomodulin, and bone morphogenetic protein 3). Comparison of this
normal cartilage proteome with the osteoarthritic one led to the iden-
tiﬁcation of 23 proteins increased in the pathologic tissue, including
aggrecan, COMP, complement factors or thrombospondin 1. We could
also identify 36 proteins that were decreased in OA cartilage, such as
type I, II and VI collagens, proteoglycans (biglycan, PRG4), tenascins or
actin.
Conclusions: In summary, proteomics strategies have demonstrated its
usefulness both for increasing the knowledge of cartilage biology and
OA pathophysiology, and also for unravelling novel proteins with
putative biomarker value of cartilage degradation in OA. The informa-
tion obtained in these studies would be of high relevance in the search
of tissue-speciﬁc OA biomarkers. Targeted veriﬁcation of these results
on a higher number of samples will be necessary for the design of ﬁnal
panels, which will be particularly useful for OA early diagnosis and
therapy studies.I-8
PROGRESS AND PITFALLS IN THE FUNCTIONAL ANALYSIS OF OA
SUSCEPTIBILITY ALLELES
R.J. Lories, F. Cornelis, S. Thysen, F. Cailotto. KU Leuven, Leuven, Belgium
Better knowledge of variation in the human genome and the availability
of novel technologies allowing the simultaneous assessment of millions
of single nucleotide polymorphisms (SNP) using DNAmicroarrays, have
dramatically changed the landscape of genetic research. Genome wide
association studies (GWAS) for complex diseases have generated awave
of enthusiasm in the community and lead to substantial progress in
understanding many chronic diseases.
However, analyzing GWAS studies in osteoarthritis is still a major
challenge. Large patient and control cohorts are necessary and pheno-
type deﬁnitions, joints of interest as well as the chronic progressive
nature of the diseases have raised enormous challenges for genetic
researchers in this ﬁeld. Nevertheless, different genetic regions have
been associated with OA. Identiﬁcation of regions or even of speciﬁc
SNPs does not directly demonstrate the involvement of a given gene.
Therefore, GWAS studies only provide a starting point to better
understand the pathophysiology of disease and the identiﬁcation of
therapeutic targets and strategies. The functional genomics approaches
includes different in vitro and in vivo models. The challenges following
GWAS are clearly illustrated by the identiﬁcation of an OA locus on
Chromosome 9 that harbors different genes which all could involved in
OA. Current evidence suggest that GPR22 and COG5 could play a role in
OA but other effects from the C9 cluster cannot be excluded.
Moreover, associated regions do not only harbor genes but also other
regulators of biological processes such as miRNAs. GWAS studies also
will only identify common variants often with limited impact on the
heritability of disease, whereas rare variants in genes may have a more
profound effect on disease development in an affected individual.
Therefore, novel technologies such as next generation sequencing likely
will provide additional tools to understand processes that deﬁne OA.
Again, functional genomic strategies identifying the roles of speciﬁc
genes and their variants in joint and joint-associated studies will be
necessary to provide a full picture.
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NEW CLINICAL TREATMENTS
X. Chevalier, Sr.. Hosp. Henri Mondor, Creteil, France
Purpose: Currently available pharmacological treatments for OA can
relieve pain temporarily, but since we don't have any therapy which
may substantially slow down the progression of the disease. Thus there
is a real need for disease modifying OA drug as well as need for drug
which act as long term pain killer. At best the “ideal” drug should both
decrease pain, improve function and acts on structure. Treatments with
cellular transplants are not under the scope of this review.
New therapeutic options in OA have largely beneﬁt from a better
understanding of the pathophysiology of OA. Osteoarthritis is now
regarded as an organ failure which associated at variable degrees,
inﬂammation of the synovial membrane, increase in the subchondral
bone turn-over and destruction of the cartilage extracellular matrix.
Aim of new therapies is focused on one of this tissue process. This
review will give an update of the available new trials in OA as well as
future possible directions.
Methods: This review has been focused on clinical studies in humans
performed with so called MeSH terms: osteoarthritis, anti NGF, bio-
logics, growths factors, subchondral bone, anti osteoporotic drugs,
stems cells, gene therapy, lubricin, PRP. PubMed Medline search was
conducted through January 2013.We also looked to abstracts frommain
OA congress and to ongoing registered clinical trials in OA.
Results: Several randomised controlled studies have nowmerged using
biologics in OA. Biologics hold considerable promise for OA therapy
since their effect in others rheumatic inﬂammatory diseases like
rheumatoid arthritis were dramatic. One should differentiate the drugs
only targeting pain such as anti nerve growth factor antibodies from the
one with a more structure disease modifying proﬁle such as anti cyto-
kine therapy. Anti NGF therapy raises promising results, though
recording of cases of rapid destructive arthropathy deserves some
caution. Biologics using anti interleukin-1 agents in knee OA raises
negative results on the evolution of pain and none study has been built
to regard the chondroprotective action of those IL-1 blockers. Tumor
necrosis alpha blockers have been tried mainly in hand OA with
